©Reuters.
PRINCETON, NJ – PDS Biotechnology, Inc. (Nasdaq: PDSB), a clinical-stage biopharmaceutical company, announced significant progress with its infectious disease vaccine platform, Infectimune®. The company’s recent preclinical research, published in the journal Vaccine, shows that its proprietary platform can improve the effectiveness of flu vaccines.
Studies have shown that the existing recombinant protein influenza vaccine Flublok®, when combined with Infectimune® (R-DOTAP), produces higher quantities and quality of multifunctional CD4 T cells compared to other anti-infectious disease adjuvants. These results suggest that Infectimune® may become a key component of the next generation of preventive vaccines, potentially providing broader protection against multiple influenza strains.
To further strengthen PDS Biotech’s position, the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 11,904,015 in February 2024. The patent is directed to a vaccine composition using the Infectimune® platform with influenza antigens to elicit T cell and antibody responses. Dr. Frank Bedu-Addo, President and CEO of PDS Biotech, said this patent strengthens the company’s intellectual property portfolio and becomes an integral part of its business strategy.
Infectimune® is currently used in the company’s universal influenza vaccine candidate PDS0202. Preclinical studies have shown that the vaccine candidate not only induces a robust immune response but also has potential advantages over existing vaccines, including the ability to provide broad cross-protective immunity against different influenza subtypes.
PDS Biotech’s product pipeline includes targeted cancer immunotherapies and infectious disease vaccines based on its proprietary T-cell activation platform. The company’s Versamune® platform has shown promising results in activating T cells that are effective against tumors, and its IL-12 fusion antibody drug conjugate (PDS01ADC) is designed to target tumors and enhance T cell activity.
This announcement is based on a press release from PDS Biotechnology Corporation. As PDS Biotech continues to advance its research and development, the company remains focused on overcoming the limitations of current immunotherapy approaches and improving the efficacy of vaccines and treatments for infectious diseases and cancer.
This article was generated and translated with the support of artificial intelligence, and has been reviewed by an editor. For more information, please see our terms and conditions.